Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07589764 · ClinicalTrials.gov registry record · Phase 1
A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS
A Phase 1 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT07589764 is a Phase 1 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 100 participants.
The verdict
NCT07589764, a Phase 1 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and Neurofilament light chain levels (NFL) and to slow ALS Functional Rating Scale, Revised (ALSFRS-R) progression.
Interventions
- DRUG β-hydroxy-β-methylbutyrate (HMB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07589764
The ClinicalTrials.gov registry entry for NCT07589764 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which β-hydroxy-β-methylbutyrate (HMB) is the first listed.
NCT07589764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07589764 about?
NCT07589764 is a clinical study titled "A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS". This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and Neurofilament light chain levels (NFL) and to slow ALS Functional Rating ...
What is the current status of trial NCT07589764?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2026-07-01. Estimated completion is 2026-08-01.
What interventions are being tested in trial NCT07589764?
The interventions under investigation include: β-hydroxy-β-methylbutyrate (HMB) (DRUG).
Who is sponsoring clinical trial NCT07589764?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.